U.S. flag

An official website of the Department of Health & Human Services

AHRQ: Agency for Healthcare Research and Quality

Search AHRQ

For an exact phrase match, enclose search terms in double quotes.

Go to Advanced Search
Go to Basic Search

Results

Total Results: 4,731 records

Showing results for "secondary".

  1. Nrd 2014 Maskedstats Core Weighted (pdf file)

    hcup-us.ahrq.gov/db/nation/nrd/stats/NRD_2014_MaskedStats_Core_Weighted.PDF
    January 01, 2014 - MYELOPROLIF DIS OR POORLY DIFF NEOPL DIAG W/O CC/MCC 1,786 0.01% 846: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY … DIAGNOSIS W MCC 12,627 0.04% 847: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS W CC 95,177 … 0.27% 848: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS W/O CC/MCC 5,298 0.02% 849: RADIOTHERAPY … 0.11% 40: Multiple myeloma 18,439 0.05% 41: Cancer; other and unspecified primary 7,459 0.02% 42: Secondary … Distribution for DXCCS1 DXCCS1 Frequency Percent of Total 99: Hypertension with complications and secondary

  2. Nrd 2012 Maskedstats Core V2 (pdf file)

    hcup-us.ahrq.gov/db/nation/nrd/stats/NRD_2012_MaskedStats_Core_V2.PDF
    January 01, 2012 - MYELOPROLIF DIS OR POORLY DIFF NEOPL DIAG W/O CC/MCC 837 0.01% 846: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY … DIAGNOSIS W MCC 4,005 0.03% 847: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS W CC 38,654 … 0.29% 848: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS W/O CC/MCC 2,936 0.02% 849: RADIOTHERAPY … 0.11% 40: Multiple myeloma 7,936 0.06% 41: Cancer; other and unspecified primary 2,917 0.02% 42: Secondary … Distribution for DXCCS1 DXCCS1 Frequency Percent of Total 99: Hypertension with complications and secondary

  3. Nrd 2011 Maskedstats Core V2 (pdf file)

    hcup-us.ahrq.gov/db/nation/nrd/stats/NRD_2011_MaskedStats_Core_V2.PDF
    January 01, 2011 - MYELOPROLIF DIS OR POORLY DIFF NEOPL DIAG W/O CC/MCC 915 0.01% 846: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY … DIAGNOSIS W MCC 3,803 0.03% 847: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS W CC 40,530 … 0.29% 848: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS W/O CC/MCC 3,395 0.02% 849: RADIOTHERAPY … 0.11% 40: Multiple myeloma 7,796 0.06% 41: Cancer; other and unspecified primary 3,033 0.02% 42: Secondary … Distribution for DXCCS1 DXCCS1 Frequency Percent of Total 99: Hypertension with complications and secondary

  4. Nrd 2011 Maskedstats Core V2 Weighted (pdf file)

    hcup-us.ahrq.gov/db/nation/nrd/stats/NRD_2011_MaskedStats_Core_V2_Weighted.PDF
    January 01, 2011 - MYELOPROLIF DIS OR POORLY DIFF NEOPL DIAG W/O CC/MCC 2,225 0.01% 846: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY … DIAGNOSIS W MCC 9,019 0.02% 847: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS W CC 100,535 … 0.27% 848: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS W/O CC/MCC 8,504 0.02% 849: RADIOTHERAPY … 0.11% 40: Multiple myeloma 18,762 0.05% 41: Cancer; other and unspecified primary 8,065 0.02% 42: Secondary … Distribution for DXCCS1 DXCCS1 Frequency Percent of Total 99: Hypertension with complications and secondary

  5. Maskedstats Nrd 2015Q1Q3 Dx Pr Grps (pdf file)

    hcup-us.ahrq.gov/db/nation/nrd/stats/MaskedStats_NRD_2015Q1Q3_Dx_Pr_Grps.PDF
    October 31, 2017 - MYELOPROLIF DIS OR POORLY DIFF NEOPL DIAG W/O CC/MCC 601 0.00% 846: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY … DIAGNOSIS W MCC 5,272 0.04% 847: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS W CC 34,050 … 0.26% 848: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS W/O CC/MCC 1,814 0.01% 849: RADIOTHERAPY … 0.11% 40: Multiple myeloma 7,302 0.06% 41: Cancer; other and unspecified primary 2,557 0.02% 42: Secondary … disease) 26,176 0.20% 98: Essential hypertension 19,541 0.15% 99: Hypertension with complications and secondary

  6. Nrd 2013 Maskedstats Core (pdf file)

    hcup-us.ahrq.gov/db/nation/nrd/stats/NRD_2013_MaskedStats_Core.PDF
    January 01, 2013 - MYELOPROLIF DIS OR POORLY DIFF NEOPL DIAG W/O CC/MCC 843 0.01% 846: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY … DIAGNOSIS W MCC 4,762 0.03% 847: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS W CC 40,324 … 0.28% 848: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS W/O CC/MCC 2,812 0.02% 849: RADIOTHERAPY … 0.12% 40: Multiple myeloma 8,257 0.06% 41: Cancer; other and unspecified primary 2,948 0.02% 42: Secondary … disease) 30,185 0.21% 98: Essential hypertension 26,413 0.18% 99: Hypertension with complications and secondary

  7. Nrd 2010 Maskedstats Core V2 (pdf file)

    hcup-us.ahrq.gov/db/nation/nrd/stats/NRD_2010_MaskedStats_Core_V2.PDF
    January 01, 2010 - MYELOPROLIF DIS OR POORLY DIFF NEOPL DIAG W/O CC/MCC 986 0.01% 846: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY … DIAGNOSIS W MCC 4,109 0.03% 847: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS W CC 41,377 … 0.30% 848: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS W/O CC/MCC 3,518 0.03% 849: RADIOTHERAPY … 0.11% 40: Multiple myeloma 7,525 0.05% 41: Cancer; other and unspecified primary 3,016 0.02% 42: Secondary … Distribution for DXCCS1 DXCCS1 Frequency Percent of Total 99: Hypertension with complications and secondary

  8. Nrd 2010 Maskedstats Core V2 Weighted (pdf file)

    hcup-us.ahrq.gov/db/nation/nrd/stats/NRD_2010_MaskedStats_Core_V2_Weighted.PDF
    January 01, 2010 - MYELOPROLIF DIS OR POORLY DIFF NEOPL DIAG W/O CC/MCC 2,437 0.01% 846: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY … DIAGNOSIS W MCC 10,023 0.03% 847: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS W CC 103,217 … 0.28% 848: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS W/O CC/MCC 7,920 0.02% 849: RADIOTHERAPY … 0.11% 40: Multiple myeloma 18,475 0.05% 41: Cancer; other and unspecified primary 7,842 0.02% 42: Secondary … Distribution for DXCCS1 DXCCS1 Frequency Percent of Total 99: Hypertension with complications and secondary

  9. Patient-Monitoring-Systems-Appendix-C (xls file)

    effectivehealthcare.ahrq.gov/sites/default/files/related_files/patient-monitoring-systems-appendix-c.xlsx
    January 01, 2024 - Primary outcomes • Hospital mortality Secondary outcomes • Composite outcome (unexpected cardiac arrests … Secondary outcomes in the meta-analysis included inhospital mortality and hospital length of stay. … Further secondary patient outcomes were reported in the narrative analysis, such as 30-day readmission … ofmaximumEDI score since admission Gallo, 2024 Arm 1 -Usual care/In person Maximum EDI <65 Rates of the secondary … Index, and timing ofmaximumEDI score since admission Gallo, 2024 Arm 2 Maximum EDI ≥65 Rates of the secondary

  10. Maskedstats Nrd 2020 Core (pdf file)

    hcup-us.ahrq.gov/db/nation/nrd/stats/MaskedStats_NRD_2020_CORE.PDF
    January 01, 2020 - POORLY DIFFERENT NEOPLASTIC DIAG WITHOUT CC/MCC 139 0.00% 846: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY … DIAGNOSIS W MCC 5,987 0.04% 846: CHEMOTHERAPY WITHOUT ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS WITH MCC … 2,051 0.01% 847: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS W CC 27,713 0.17% 847: CHEMOTHERAPY … WITHOUT ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS WITH CC 9,009 0.05% 848: CHEMOTHERAPY W/O ACUTE LEUKEMIA … AS SECONDARY DIAGNOSIS W/O CC/MCC 956 0.01% 848: CHEMOTHERAPY WITHOUT ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS

  11. Maskedstats Nrd 2020 Core Weighted (pdf file)

    hcup-us.ahrq.gov/db/nation/nrd/stats/MaskedStats_NRD_2020_Core_Weighted.PDF
    January 01, 2020 - POORLY DIFFERENT NEOPLASTIC DIAG WITHOUT CC/MCC 251 0.00% 846: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY … DIAGNOSIS W MCC 11,438 0.04% 846: CHEMOTHERAPY WITHOUT ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS WITH MCC … 3,926 0.01% 847: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS W CC 54,599 0.17% 847: CHEMOTHERAPY … WITHOUT ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS WITH CC 17,599 0.05% 848: CHEMOTHERAPY W/O ACUTE LEUKEMIA … AS SECONDARY DIAGNOSIS W/O CC/MCC 1,960 0.01% 848: CHEMOTHERAPY WITHOUT ACUTE LEUKEMIA AS SECONDARY

  12. Neds 2013 Maskedstats Ip (pdf file)

    hcup-us.ahrq.gov/db/nation/neds/stats/NEDS_2013_MaskedStats_IP.PDF
    January 01, 2013 - MYELOPROLIF DIS OR POORLY DIFF NEOPL DIAG W/O CC/MCC 240 0.01 846: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY … DIAGNOSIS W MCC 75 0.00 847: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS W CC 292 0.01 … 848: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS W/O CC/MCC 22 0.00 849: RADIOTHERAPY 19 … DIAGNOSIS W MCC 75 0.00 847: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS W CC 292 0.01 … 848: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS W/O CC/MCC 22 0.00 849: RADIOTHERAPY 19

  13. Neds 2014 Maskedstats Ip (pdf file)

    hcup-us.ahrq.gov/db/nation/neds/stats/NEDS_2014_MaskedStats_IP.PDF
    January 01, 2014 - MYELOPROLIF DIS OR POORLY DIFF NEOPL DIAG W/O CC/MCC 227 0.01 846: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY … DIAGNOSIS W MCC 77 0.00 847: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS W CC 229 0.01 … 848: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS W/O CC/MCC 12 0.00 849: RADIOTHERAPY 34 … DIAGNOSIS W MCC 77 0.00 847: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS W CC 229 0.01 … 848: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS W/O CC/MCC 12 0.00 849: RADIOTHERAPY 34

  14. ADHD Medications and Risk of Serious Coronary Heart Disease in Yough and Middle-Aged Adults (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/pdf/adhd-heart-disease-children_research.pdf
    January 01, 2023 - A secondary source was hospital discharge data, including emergency department (ED) records. … To be included, ventricular tachycardia needed to be accompanied by a secondary discharge diagnosis … In secondary analyses, all variables in the CRS were fixed at baseline to address concerns that some … Instead, we chose to conduct secondary analyses using remote users as our comparison group. … our adjustment for multiple established and potential CVD risk factors, our findings from several secondary

  15. Spreading Lean: Taking Efficiency Interventions in Health Services Delivery to Scale | Agency for Healthcare Research and Quality

    www.ahrq.gov/practiceimprovement/delivery-initiative/execsumm.html
    June 01, 2017 - The findings reported here are based on primary and secondary data sources at PAMF, including: Nearly

  16. A Sweet Case of Hidden Hydrogen Ions | PSNet

    psnet.ahrq.gov/web-mm/sweet-case-hidden-hydrogen-ions
    November 30, 2023 - August 1, 2019 WebM&M Cases Primary Workaround, Secondary

  17. Uterine Artery Injury during Cesarean Delivery Leads to Cardiac Arrests and Emergency Hysterectomy | PSNet

    psnet.ahrq.gov/web-mm/uterine-artery-injury-during-cesarean-delivery-leads-cardiac-arrests-and-emergency
    September 30, 2020 - Multiple protocols and clinical pathways have been developed to reduce maternal morbidity and mortality secondary

  18. Layout 1 (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/related_files/ace-inhibitor-arb-update_executive.pdf
    June 01, 2011 - Secondary outcomes: • Lipid levels (high-density lipoprotein, low-density lipoprotein, total cholesterol

  19. Sources of NIS Data and State-Specific Restrictions 2004

    hcup-us.ahrq.gov/db/nation/nis/nis_2004_stspecific_restr.jsp
    January 01, 2004 - 75 and above 75 The HIV or drug/alcohol use patients are identified by any principal or secondary

  20. Nis Sources And Restrictions 2002 (pdf file)

    hcup-us.ahrq.gov/db/nation/nis/NIS_Sources_and_Restrictions_2002.pdf
    January 01, 2002 - -74 69 75 and above 75 The HIV or drug/alcohol use patients are identified by any principal or secondary
SHARE:
Facebook Twitter Print Facebook Share

Similar Terms:

Search the AHRQ Archive

Information and reports more than 5 years old may be found in the AHRQ Archive site.

Search Archive

Search Within A Specific AHRQ Site

Click to show only results for the selected site.

psnet.ahrq.gov (1194)

hcup-us.ahrq.gov (1163)

effectivehealthcare.ahrq.gov (808)

www.ahrq.gov (718)

digital.ahrq.gov (414)

www.uspreventiveservicestaskforce.org (380)

cds.ahrq.gov (21)

cdsic.ahrq.gov (13)

meps.ahrq.gov (7)

integrationacademy.ahrq.gov (5)

datatools.ahrq.gov (3)

qualityindicators.ahrq.gov (3)

pso.ahrq.gov (2)